Epistem’s Biomarker Focus in the US

21-Oct-2009 - USA

Epistem Plc will open a US office based in Boston, MA to increase its presence in the all important North American Market. The US office (‘Epistem Inc’) will support the commercialisation of the recently launched proprietary GenetRxTM biomarker platform in oncology.

Epistem’s biomarker collaborations in North America will focus on preclinical and clinical oncology drug development providing a means of translating drug effect in specific oncology pathways such as Hedgehog, WNT, Notch, Beta Catenin, PI3 kinase and androgen signalling as well as providing an ideal platform for evaluating therapies aimed at specific RNA targets. The Biomarker Laboratory services will be delivered within a regulatory framework to comply with Good Clinical Laboratory Practice (GcLP).

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance